I like this part“We made significant progress with both NUCRYST and iFire in 2002,” said Barry M. Heck, President & CEO of Westaim. “In 2003 we will build on last year’s accomplishments as NUCRYST enters its first human trials for a drug based on its nanocrystalline technology and iFire begins to work on product-sized, mid-30-inch flat panel displays.”
My e-mail from WED.The risk in this stock is low if none
at all.The CEO change was huge.Will pick up more shares
at this level.